Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
주식 순위 #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
주가
$910.55
시가총액
$860.30B
변동 (1일)
0.44%
변동 (1년)
5.28%
국가
US
거래 Eli Lilly (LLY)

카테고리

Eli Lilly (LLY)의 매출
Dec 2025 기준 매출 TTM: $65.18B
Eli Lilly의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $65.18B입니다. 2024년에 회사는 $45.04B의 수익을 올렸으며 이는 2023년의 $34.12B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Eli Lilly의 수익 기록 (2000 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $65.18B 0.00%
2025 $65.18B 44.70%
2024 $45.04B 32.00%
2023 $34.12B 19.56%
2022 $28.54B 0.79%
2021 $28.32B 15.40%
2020 $24.54B 9.95%
2019 $22.32B 3.84%
2018 $21.49B 7.61%
2017 $19.97B -5.88%
2016 $21.22B 6.33%
2015 $19.96B 1.75%
2014 $19.62B -15.13%
2013 $23.11B 2.25%
2012 $22.60B -6.93%
2011 $24.29B 5.25%
2010 $23.08B 5.68%
2009 $21.84B 7.19%
2008 $20.37B 9.33%
2007 $18.63B 18.75%
2006 $15.69B 7.14%
2005 $14.65B 5.68%
2004 $13.86B 10.14%
2003 $12.58B 13.59%
2002 $11.08B -4.03%
2001 $11.54B 6.26%
2000 $10.86B 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$58.74B -9.88%
GB
$94.19B 44.51%
US
$61.16B -6.17%
US
$56.15B -13.85%
CH
$65.01B -0.26%
US